Skip to main content
. 2022 Oct 21;25(Suppl 6):e26009. doi: 10.1002/jia2.26009
Abstract P090 – Table 1. Week 48 efficacy (ITT‐E population, Snapshot) and safety (safety populationa) results from the pooled analysis of the TANGO and SALSA trials.
White Black Asian Other racesb
DTG/3TC CAR DTG/3TC CAR DTG/3TC CAR DTG/3TC CAR
Efficacy parameter (N = 445) (N = 433) (N = 96) (N = 106) (N = 44) (N = 52) (N = 30) (N = 28)
HIV‐1 RNA ≥50 copies/mL, n (%) 0 2 (<1) 1 (1) 2 (2) 0 1 (2) 1 (3) 0
HIV‐1 RNA <50 copies/mL, n (%) 418 (94) 405 (94) 88 (92) 96 (91) 42 (95) 49 (94) 28 (93) 25 (89)
CD4+ count, cells/mm3
Baseline, mean (SD) 718.3 729.9 747.6 751.5 576.2 577.9 667.1 653.6
(301.2) (277.7) (322.2) (285.7) (196.4) (236.7) (329.1) (284.1)
Adjusted mean change (SE)c 25.0 ‐1.5 42.6 ‐12.3 ‐30.5 18.2 6.8 ‐13.5
(8.4) (8.2) (18.3) (17.0) (26.9) (24.2) (32.0) (32.7)
CD4+/CD8+ ratio
Baseline, mean (SD) 1.1 (0.6) 1.1 (0.5) 1.1 (0.6) 1.2 (0.6) 0.9 (0.4) 0.9 (0.4) 1.0 (0.3) 1.0 (0.4)
Adjusted mean change (SE)d 0.039 0.056 0.041 0.045 0.021 0.033 0.027 0.064
(0.0097) (0.0104) (0.0211) (0.0215) (0.0308) (0.0304) (0.0365) (0.0412)
White Black Asian Other racesb
DTG/3TC CAR DTG/3TC CAR DTG/3TC CAR DTG/3TC CAR
Safety parameter, n (%) (N = 445) (N = 432) (N = 96) (N = 106) (N = 44) (N = 52) (N = 30) (N = 28)
Any AE 344 (77) 331 (77) 72 (75) 77 (73) 33 (75) 38 (73) 26 (87) 18 (64)
AEs leading to withdrawal 14 (3) 3 (<1) 2 (2) 2 (2) 2 (5) 0 0 0
Grade 2 to 5 AEs 205 (46) 215 (50) 42 (44) 51 (48) 17 (39) 24 (46) 17 (57) 13 (46)
Drug‐related AEs 60 (13) 9 (2) 16 (17) 3 (3) 8 (18) 8 (15) 9 (30) 1 (4)
Any SAE 18 (4) 18 (4) 6 (6) 9 (8) 3 (7) 4 (8) 1 (3) 1 (4)

3TC, lamivudine; CAR, current antiretroviral regimen; DTG, dolutegravir; MMRM, mixed‐models repeated‐measures.

aIn TANGO, one participant was found to be taking a TDF‐based regimen and was excluded from the safety population;

bincludes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, mixed White race, and multiple races;

cMMRM analysis adjusting for treatment; visit; age; sex; baseline CD4+ cell count; baseline third agent; baseline BMI; race; study (combined analysis only); and treatment‐by‐visit, baseline CD4+ cell count‐by‐visit, visit‐by‐race, treatment‐by‐race, and treatment‐by‐visit‐by‐race interactions, with visit as repeated factor;

dMMRM analysis adjusting for treatment; visit; age; sex; baseline CD4+ cell count; baseline third agent; baseline CD4+/CD8+ ratio; baseline BMI; race; study (combined analysis only); and treatment‐by‐visit, baseline CD4+/CD8+ ratio‐by‐visit, visit‐by‐race, treatment‐by‐race, and treatment‐by‐visit‐by‐race interactions, with visit as repeated factor.